Buprenorphine TTS for children - A review of the drug's clinical pharmacology

Paediatric Anaesthesia

Volumn 21, Issue 3, 2011, Pages 280-290

  Michel, Erik ^a   Anderson, Brian J ^b   Zernikow, Boris ^c  

^a Klinikum Offenburg   (Germany)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

analgesia; buprenorphine; ceiling effect; child; norbuprenorphine; respiratory depression; transdermal; TTS

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUPRENORPHINE; CYTOCHROME P450 3A4; DIPYRONE; GLUCURONOSYLTRANSFERASE; MIDAZOLAM; MORPHINE; NALOXONE; NOCICEPTIN; OPIATE RECEPTOR; PARACETAMOL; TILIDINE;

ABSTINENCE; CANCER PAIN; CARCINOGENICITY; CHRONIC PAIN; DRUG BIOAVAILABILITY; DRUG FATALITY; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; LIVER INJURY; MOLECULAR WEIGHT; NEUROPATHIC PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TERATOGENICITY;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CHILD; DRUG DELIVERY SYSTEMS; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; PAIN; PAIN, POSTOPERATIVE; RECEPTORS, OPIOID, MU; RESPIRATORY INSUFFICIENCY; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 79951645459     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2010.03437.x     Document Type: Review

References (77)

1. Boas RA, Villiger JW,. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth 1985; 57: 192-196. (Pubitemid 15093410)
2. Maunuksela EL, Korpela R, Olkkola KT,. Comparison of buprenorphine with morphine in the treatment of postoperative pain in children. Anesth Analg 1988; 67: 233-239. (Pubitemid 18078264)
3. Olkkola KT, Maunuksela EL, Korpela R,. Pharmacokinetics of intravenous buprenorphine in children. Br J Clin Pharmacol 1989; 28: 202-204. (Pubitemid 19201415)
4. Kamal RS, Khan FA,. Caudal analgesia with buprenorphine for postoperative pain relief in children. Paediatr Anaesth 1995; 5: 101-106.
5. Maunuksela EL, Korpela R, Olkkola KT,. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain of children. Br J Anaesth 1988; 60: 48-55. (Pubitemid 18053015)
6. Gangopadhyay AN, Bhattacharya P, Sinha A, et al. Caudal epidural buprenorphine for postoperative pain relief in children. Pediatr Surg Int 1992; 7: 124-125.
7. Lone AQ, Naqash I, Qazi S, et al. Role of buprenorphine hydrochloride in attenuating the haemodyanamic, hormonal and metabolic responses to surgery in children. JK Pract 1998; 5: 300-302. (Pubitemid 28518293)
8. Massimo L, Haupt R, Enrica M,. Control of pain with sublingual buprenorphine in children with cancer. Pediatr Hematol Oncol 1985; 2: 224.
9. Girotra S, Kumar S, Rajendran KM,. Postoperative analgesia in children who have genito-urinary surgery. A comparison between caudal buprenorphine and bupivacaine. Anaesthesia 1990; 45: 406-408. (Pubitemid 20149930)
10. Girotra S, Kumar S, Rajendran KM,. Comparison of caudal morphine and buprenorphine for post-operative analgesia in children. Eur J Anaesthesiol 1993; 10: 309-312. (Pubitemid 23206364)
11. Girotra S, Kumar S, Rajendran KM,. Caudal buprenorphine for postoperative analgesia in children: a comparison with intramuscular buprenorphine. Acta Anaesthesiol Scand 1993; 37: 361-364. (Pubitemid 23155842)
12. Geib AJ, Babu K, Ewald MB, et al. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics 2006; 118: 1746-1751. (Pubitemid 46393828)
13. Gaulier JM, Charvier F, Monceaux F, et al. Ingestion of high-dose buprenorphine by a 4 year-old child. J Toxicol Clin Toxicol 2004; 42: 993-995. (Pubitemid 40024267)
14. Budd K,. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl 2003; 133: 9-14. (Pubitemid 36362950)
15. Sittl R,. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother 2005; 5: 315-323. (Pubitemid 40705273)
16. Likar R, Kayser H, Sittl R,. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006; 28: 943-952. (Pubitemid 44062699)
17. Griessinger N, Sittl R, Likar R,. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 2005; 21: 1147-1156. (Pubitemid 41140716)
18. Zernikow B, Schiessl C, Wamsler C, et al. [Long-term pediatric opioid based pain control. Case reports]. Schmerz 2005; 19: 418-425. (Pubitemid 41380767)
19. Evans HC, Easthope SE,. Transdermal buprenorphine. Drugs 2003; 63: 1999-2010. discussion 2011-2. (Pubitemid 37222571)
20. Reidenberg B, El-Tahtawy A, Munera C, et al. Absolute bioavailability of a novel buprenorphine transdermal system (BTDS). J Clin Pharmacol 2001; 41: 1026.
21. Deandrea S, Corli O, Moschetti I, et al. Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review. Ther Clin Risk Manag 2009; 5: 707-718.
22. Kress HG,. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009; 13: 219-230.
23. Skaer TL,. Transdermal opioids for cancer pain. Health Qual Life Outcomes 2006; 4: 24.
24. Johnson RE, Fudala PJ, Payne R,. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005; 29: 297-326. (Pubitemid 40386746)
25. Zanette G, Manani G, Giusti F, et al. Respiratory depression following administration of low dose buprenorphine as postoperative analgesic after fentanyl balanced anaesthesia. Paediatr Anaesth 1996; 6: 419-422. (Pubitemid 126444261)
26. Zola EM, McLeod DC,. Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Drug Intell Clin Pharm 1983; 17: 411-417. (Pubitemid 13098541)
27. Gal TJ,. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 1989; 45: 66-71. (Pubitemid 19047148)
28. Koppert W, Ihmsen H, Korber N, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005; 118: 15-22. (Pubitemid 41566581)
29. Vanderah TW, Laughlin T, Lashbrook JM, et al. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 1996; 68: 275-281. (Pubitemid 27025885)
30. Simonnet G,. Opioids: from analgesia to anti-hyperalgesia? Pain 2005; 118: 8-9. (Pubitemid 41566579)
31. Likar R, Sittl R,. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 2005; 100: 781-785. (Pubitemid 40300077)
32. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94: 825-834. (Pubitemid 40754001)
33. Lutfy K, Cowan A,. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004; 2: 395-402. (Pubitemid 39276631)
34. Negus SS, Bidlack JM, Mello NK, et al. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 2002; 13: 557-570. (Pubitemid 35387416)
35. Vadivelu N, Hines RL,. Buprenorphine: a unique opioid with broad clinical applications. J Opioid Manag 2007; 3: 49-58. (Pubitemid 350199793)
36. Hamunen K, Olkkola KT, Maunuksela EL,. Comparison of the ventilatory effects of morphine and buprenorphine in children. Acta Anaesthesiol Scand 1993; 37: 449-453. (Pubitemid 23203952)
37. Barrett DA, Simpson J, Rutter N, et al. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol 1993; 36: 215-219. (Pubitemid 23275338)
38. Chay PC, Duffy BJ, Walker JS,. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin Pharmacol Ther 1992; 51: 334-342.
39. Staats PS, Johnson RE,. New perspectives on the pharmacology of opioids and their use in chronic pain. Prog Anaesthesiol 2002; 16: 235-249.
40. Dahan A,. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 2006; 20 (Suppl. 1): s3-s8. (Pubitemid 43871328)
41. Hull CJ, Van Beem HB, McLeod K, et al. A pharmacodynamic model for pancuronium. Br J Anaesth 1978; 50: 1113-1123. (Pubitemid 9058499)
42. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to D-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-371. (Pubitemid 9164953)
43. Yassen A, Olofsen E, Romberg R, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 2006; 104: 1232-1242. (Pubitemid 43852957)
44. Yassen A, Kan J, Olofsen E, et al. Mechanism-based pharmacokinetic- pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther 2006; 319: 682-692.
45. Cowan A,. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl 2003; 133: 3-8. (Pubitemid 36362949)
46. Ohtani M, Kotaki H, Nishitateno K, et al. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281: 428-433. (Pubitemid 27203097)
47. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272: 505-510.
48. Picard N, Cresteil T, Djebli N, et al. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 2005; 33: 689-695. (Pubitemid 40593885)
49. Tegeder I, Lotsch J, Geisslinger G,. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37: 17-40.
50. Boger RH,. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006; 20 (Suppl. 1): s17-s23. (Pubitemid 43871330)
51. Olkkola KT, Hamunen K, Maunuksela EL,. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 1995; 28: 385-404.
52. Bullingham RE, McQuay HJ, Moore A, et al. Buprenorphine kinetics. Clin Pharmacol Ther 1980; 28: 667-672. (Pubitemid 11254168)
53. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
54. Anderson BJ, Meakin GH,. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr Anaesth 2002; 12: 205-219. (Pubitemid 34264439)
55. Zernikow B, Michel E, Anderson BJ,. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J Pain 2007; 8: 187-207. (Pubitemid 46366861)
56. Cowan A, Doxey JC, Harry EJ,. The animal pharmacology of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977; 60: 547-554. (Pubitemid 8149540)
57. Stone S,. Case report of buprenorphine hydrochloride (subutex) in a 4-year-old asthmatic male. J Subst Use 2002; 7: 124. (Pubitemid 35153732)
58. Hayes BD, Klein-Schwartz W, Doyon S,. Toxicity of buprenorphine overdoses in children. Pediatrics 2008; 121: e782-e786.
59. Sacerdote P,. Opioids and the immune system. Palliat Med 2006; 20 (Suppl. 1): s9-s15. (Pubitemid 43871329)
60. Martucci C, Panerai AE, Sacerdote P,. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain 2004; 110: 385-392. (Pubitemid 38953304)
61. Mello NK, Bree MP, Mendelson JH,. Buprenorphine self-administration by rhesus monkey. Pharmacol Biochem Behav 1981; 15: 215-225. (Pubitemid 11054617)
62. Mello NK, Mendelson JH, Lukas SE, et al. Buprenorphine treatment of opiate and cocaine abuse: clinical and preclinical studies. Harv Rev Psychiatry 1993; 1: 168-183.
63. Lindemalm S, Nydert P, Svensson JO, et al. Transfer of buprenorphine into breast milk and calculation of infant drug dose. J Hum Lact 2009; 25: 199-205.
64. Bandstra ES, Morrow CE, Mansoor E, et al. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis 2010; 29: 245-258.
65. Blaylock M, Engelhardt T, Bissonnette B,. Fundamentals of neuronal apoptosis relevant to pediatric anesthesia. Paediatr Anaesth 2010; 20: 383-395.
66. Attina G, Ruggiero A, Maurizi P, et al. Transdermal buprenorphine in children with cancer-related pain. Pediatr Blood Cancer 2009; 52: 125-127.
67. Hunt A, Goldman A, Seers K, et al. Clinical validation of the paediatric pain profile. Dev Med Child Neurol 2004; 46: 9-18. (Pubitemid 38120445)
68. Vander Hulst K, Parera Amer E, Jacobs C, et al. Allergic contact dermatitis from transdermal buprenorphine. Contact Dermatitis 2008; 59: 366-369.
69. Perez-Perez L, Cabanillas M, Loureiro M, et al. Allergic contact dermatitis due to transdermal buprenorphine. Contact Dermatitis 2008; 58: 310-312. (Pubitemid 351537612)
70. Hasani VA, Amanni A, Poureslami M, et al. Paediatric premedication: a comparison of sublingual buprenorphine and midazolam in children (4-10 years) scheduled for adenotonsillectomy. Iran J Pharmacol Ther 2002; 1: 12-16.
71. Khan FA, Hamdani GA,. Comparison of intrathecal fentanyl and buprenorphine in urological surgery. J Pak Med Assoc 2006; 56: 277-281. (Pubitemid 46768699)
72. Levy S, Vaughan BL, Angulo M, et al. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program. J Adolesc Health 2007; 40: 477-482. (Pubitemid 46590021)
73. Kraft WK, Gibson E, Dysart K, et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. Pediatrics 2008; 122: e601-e607.
74. Maruyama S, Nomura Y, Fukushige T, et al. Suspected takotsubo cardiomyopathy caused by withdrawal of bupirenorphine in a child. Circ J 2006; 70: 509-511.
75. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332. (Pubitemid 351738156)
76. Budd K,. Buprenorpine: a review. Evidence Based Medicine in Practice. Newmarket: Hayward Medical Communications, 2002.
77. Khan FA, Memon GA, Kamal RS,. Effect of route of buprenorphine on recovery and postoperative analgesic requirement in paediatric patients. Paediatr Anaesth 2002; 12: 786-790. (Pubitemid 36051347)